Full-Time

Medical Affairs Scientist

Updated on 9/13/2026

Deadline 9/26/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

İzmir, Türkiye

Remote

PhD, MD

Category
Biology & Biotech
Required Skills
CRM
Risk Management

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • Understanding of medical plans and budget management.
  • Understanding of medical governance and collaboration across cross-functional teams.
  • Understanding of medical writing and comprehensive medical review of documents.
  • Ability to communicate with different stakeholders across different channels.
  • External engagement competencies, including networking and stakeholder mapping and management.
  • Ability to focus on priorities, demonstrate resilience and organization, and apply project management competencies.
  • Fluent Turkish and English language skills.
  • Ability to lead complex projects involving multiple external and internal stakeholders.
  • Business acumen and a high level of industry understanding.
  • Experience setting up and developing networks.
  • Education as a Medical Doctor or Pharmacist with a Ph.D.
Responsibilities
  • Provide deep medical and scientific expertise to healthcare professionals, professional associations, patient groups, and other relevant decision makers.
  • Develop and deliver the local medical strategy and life-cycle clinical plans for medicines in the nominated therapy area.
  • Communicate the safe and appropriate use and value of medicines to improve patient outcomes, enhance clinical practice, and support business needs.
  • Demonstrate the value of innovative medicines through real-world evidence.
  • Create digital educational and scientific content across relevant channels and formats.
  • Champion the patient voice when developing and implementing medical strategies.
  • Provide subject matter expertise and scientific exchange, capturing insights through customer relationship management tools and informal interactions.
  • Provide focused information in response to clinician and patient needs.
  • Establish research partnerships and build academic and research collaborations within the nominated therapy area.
  • Establish relationships with healthcare professionals, specialists, patient groups, and other decision makers.
  • Liaise with healthcare professionals to communicate and manage drug safety issues.
  • Provide medical and scientific input to internal teams supporting appropriate medicine use and implementation of initiatives and programs.
  • Identify data gaps and develop local real-world data and real-world evidence for product value and market access.
  • Deliver medical activities including educational materials, real-world evidence, non-interventional studies, database studies, and registries, and ensure timely publication of data.
  • Evaluate requests supporting medical education, quality improvement, health services research, investigator-sponsored research, and clinical research collaborations.
  • Provide medical and scientific input into protocol feasibility assessments for clinical trial proposals.
  • Identify appropriate investigators and sites for company-sponsored clinical trials.
  • Collaborate with clinical research colleagues and global teams to complete company-sponsored clinical trials on time.
  • Provide input to clinical development teams on trials relevant to Turkey, using clinician, payer, and patient insights.
  • Implement approved compassionate-use and named-patient supply programs.
  • Present accurate, balanced, and specific information to healthcare professionals and other decision makers in response to unsolicited requests.
  • Lead local advisory boards to gain clinical and patient insights.
  • Work with patients and patient organizations to understand unmet medical needs and center the patient voice in medical strategies and projects.
  • Present the medical perspective on selected topics during media briefings.
  • Provide scientific insights and support to field- and head-office-based commercial colleagues.
  • Provide medical expertise for regulatory and market access strategies, including licensing and access schemes, regulatory and health technology assessment submissions, and adaptive pathways.
  • Provide medical expertise for regulatory labeling updates, risk management plans, and license maintenance.
  • Provide clinical input to Medical Information for maintaining and creating standard response documents.
  • Develop and maintain cross-functional collaboration between global and local country teams.
  • Identify opportunities for customer-focused digital solutions and contribute to their creation with Medical Affairs Strategy and Execution and Digital Medical teams.
  • Perform customer-facing medical activities for assigned products according to priorities defined with the manager.
  • Review and sign off on promotional materials and company-sponsored activities for compliance with local product information and requirements.
  • Work with Medical Affairs Excellence, Medical Affairs Strategy and Execution, Digital Medical, Real World Data, Medical Quality Governance, Compliance, Legal, and other cross-functional teams.
Desired Qualifications
  • Pharmaceutical industry experience within medical affairs.
  • Good knowledge of national healthcare and medicine funding and reimbursement systems.
  • Knowledge of health economics, pharmacovigilance, and regulatory affairs.
  • Experience generating real-world data and real-world evidence in healthcare.
  • Experience in clinical research.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.